Cancer Diagnostics Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	176 Pages	Coherent Market Insights	July, 2023	CMI18107919

Best Price Guarantee
Price	from $4,500
Length	176 Pages
Publisher	Coherent Market Insights
Published Date	July, 2023
SKU	CMI18107919

Cancer Diagnostics Market, By Test Type (Tumor Biomarkers Tests (PSA Tests, CTC Tests, AFP Tests, CA-19 Tests, HER2 Tests, BRCA Tests, ALK Tests, CEA Tests, EGFR Mutation Tests, KRAS Mutation Tests, Others)), Imaging (Ultrasound, Mammography, MRI Scan, PET Scan, CT Scan, SPECT & Others), Biopsy (Needle Biopsy, Endoscopic Biopsy, Bone Marrow Biopsy, Others), Liquid Biopsy Immunohistochemistry In Situ Hybridization), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancers, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver Cancer, Others), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Cancer is a large group of diseases that can start in almost any organ or tissue of the body when abnormal cells grow uncontrollably, go beyond their usual boundaries to invade adjoining parts of the body, and/or spread to other organs. The latter process is called metastasizing and is a major cause of death from cancer. A neoplasm and malignant tumor are other common names for cancer. Tumor biomarkers test used in the diagnosis of cancer include, prostate-specific antigen (PSA), circulating tumor cells (CTC), Alfa-fetoprotein test (AFP), CA-19 test for pancreatic cancer, HER-2 test, BRCA test, ALK test for lung cancer, carcinoembryonic test (CEA), EGFR mutation test, and RAS mutation test.

Market Dynamics

The key market players are focusing on the adoption of growth organic strategies such as launching new cancer diagnostics, which is attributed to the growth of the global cancer diagnostics market. For instance, in March 2020, BD (Becton, Dickinson and Company) a medical technology company, and BioMedomics, a privately held, U.S.-based clinical diagnostics company, announced the release of a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to PARP biomarker test in as little as 15 minutes. Furthermore, the development of new technologically advanced products for cancer diagnosis is expected to support market growth. In November 2021, Siemens Healthineers launched Naeotom Alpha, the globe's first photon-counting CT Scannerwith improved resolution as well as a reduction in radiation dose by up to 45% for ultra-high resolution scans. Thus, the segment is expected to show growth in the near future due to the above-mentioned factors.

Furthermore, governments and other healthcare organizations are taking initiatives to provide women between 50 to 75 years access to mammography screening. In June 2020, Fujifilm Medical Systems is Medical equipment manufacturer in the U.S.A. announced a new breast cancer screening awareness campaign focused on early detection of the disease in the United States. The ‘Aspire to Be Fearless’ campaign involves a mobile mammography vehicle traveling throughout the United States to spread Fujifilm’s message. The vehicle includes a waiting room, dressing room, and the latest breast imaging solutions from Fujifilm.

Key features of the study:

This report provides an in-depth analysis of the global cancer diagnostics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new test launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global cancer diagnostics market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc. Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, Bio Rad Laboratories Inc., Exagen Inc., Genway Biotech, Inc., Microdrop LLC (imaware), Svar Life Science AB, Abbott Laboratories, Thermo Fisher Scientific Inc., Bio Rad Laboratories Inc., GE Healthcare, Illumina, Inc., Koninklijke Philips N.V., Toshiba Medical Systems Corporation, Agilent Technologies, Inc., Aurora Imaging Technologies, Inc., and Quest Diagnostics.
Global cancer diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer diagnostics market.

Detailed Segmentation:

Global Cancer Diagnostics Market, By Test Type:
PSA Tests
CTC Tests
AFP Tests
CA-19 Tests
HER2 Tests
BRCA Tests
ALK Tests
CEA Tests
EGFR Mutation Tests
KRAS Mutation Tests
Others
Ultrasound
Mammography
MRI Scan
PET Scan
CT Scan
Needle Biopsy
Endoscopic Biopsy
Bone Marrow Biopsy
Others
Tumor Biomarkers Tests
Imaging
Biopsy
Liquid Biopsy
Immunohistochemistry
In Situ Hybridization
Global Cancer Diagnostics Market, By Cancer Type:
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Blood Cancers
Prostate Cancer
Ovarian Cancer
Stomach Cancer
Liver Cancer
Others
Global Cancer Diagnostics Market, By End User:
Hospital Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
Global Cancer Diagnostics, By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles
Myriad Genetics, Inc
F. Hoffmann-La Roche AG
Invitae Corporation
NeoGenomics Laboratories, Inc.
BPS Bioscience, Inc.
Antibodies Inc.
Networks LLC
Beckman Coulter, Inc.
Euro Diagnostica AB
F. Hoffmann-La Roche Ltd.
Qiagen NV
Siemens Healthcare GmbH
Bio Rad Laboratories Inc.
Exagen Inc.
Genway Biotech, Inc.
Microdrop LLC (imaware)
Svar Life Science AB
Thermo Fisher Scientific Inc.
Bio Rad Laboratories Inc.
GE Healthcare
Illumina, Inc.
Koninklijke Philips N.V.
Toshiba Medical Systems Corporation
Agilent Technologies, Inc.
Aurora Imaging Technologies, Inc.
Quest Diagnostics.

1. Research Objective and Assumption: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snippet, By c; Market Snippet, By Cancer Type; Market Snippet, By End User; Market Snippet, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Recent Test Launches; Epidemiology; Merger, Acquisition, and Collaboration; Regulatory Scenario; Key Developments; PEST Analysis
4. Global Cancer Diagnostics Market – COVID-19 Impact Analysis: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global Cancer Diagnostics Market, By Test Type, 2018 – 2030 (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; Tumor Biomarkers Tests; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Segment Trends; PSA Tests; CTC Tests; AFP Tests; CA-19 Tests; HER2 Tests; BRCA Tests; ALK Tests; CEA Tests; EGFR Mutation Tests; KRAS Mutation Tests; Others; Imaging; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Segment Trends; Ultrasound; Mammography; MRI Scan; PET Scan; CT Scan; Biopsy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Segment Trends; Needle Biopsy; Endoscopic Biopsy; Bone Marrow Biopsy; Others; Liquid Biopsy; Immunohistochemistry; In Situ Hybridization
6. Global Cancer Diagnostics Market, By Cancer Type 2018 – 2030 (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; Breast Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Lung Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Colorectal Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Melanoma; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Blood Cancers; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Prostate Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Ovarian Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Stomach Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Liver Cancer; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
7. Global Cancer Diagnostics Market, By End User 2018 – 2030 (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; Hospital Associated Labs; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Independent Diagnostic Laboratories; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Diagnostic Imaging Centers; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Cancer Research Institutes; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
8. Global Cancer Diagnostics Market, By Regions, 2018 – 2030 (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018–2030; Segment Trends; North America; Introduction; Market Size and Forecast, By Test Type, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By Cancer Type, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By End User, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Bn); U.S.; Canada; Europe; Introduction; Market Size and Forecast, By Test Type, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By Cancer Type, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By End User, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Bn); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, By Test Type, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By Cancer Type, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By End User, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Bn); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Latin America; Introduction; Market Size and Forecast, By Test Type, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By Cancer Type, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By End User, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Brazil; Mexico; Argentina; Rest of Latin America; Middle East; Introduction; Market Size and Forecast, By Test Type, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By Cancer Type, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By End User, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Bn); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, By Test Type, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By Cancer Type, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By End User, and Y-o-Y Growth 2018 – 2030, (US$ Bn); Market Size and Forecast, By Country, and Y-o-Y Growth 2018 – 2030, (US$ Bn); North Africa; Central Africa; South Africa
9. Competitive Landscape: Company Profiles; Myriad Genetics, Inc.; Company Overview; Product Portfolio; Key Highlights; Financial Overview; Strategies; F. Hoffmann-La Roche AG; Invitae Corporation; NeoGenomics Laboratories, Inc.; BPS Bioscience; Antibodies Inc.; Networks LLC; Beckman Coulter, Inc.; Euro Diagnostica AB, F.; Qiagen NV; Siemens Healthcare GmbH; Augurex Life Sciences Corp.; Thermo Fisher Scientific Inc.; Bio Rad Laboratories Inc.; Exagen Inc.; Genway Biotech, Inc.; Microdrop LLC (imaware); Svar Life Science AB; Thermo Fisher Scientific Inc.; Bio Rad Laboratories Inc.; GE Healthcare; Illumina, Inc.; Koninklijke Philips N.V.; Toshiba Medical Systems Corporation; Agilent Technologies, Inc.; Aurora Imaging Technologies, Inc.; Quest Diagnostics.
10. Section: References; Research Methodology; About us and Sales Contact; *Browse 34 market data tables and 26 figures on “Global Cancer Diagnostics Market – Global forecast to 2030